Earle A. Chiles Research Institute

  • New clinical studies for invasive breast cancer

    New clinical studies for invasive breast cancer

    Providence Cancer Institute breast cancer experts are researching new treatments for women with triple-negative breast cancer and HER-2 positive breast cancer.

    Read Article
  • New research laboratory employs biomedical engineering for precision cancer surgery

    New research laboratory employs biomedical engineering for precision cancer surgery

    Experts in biomedical engineering, immunology and surgical oncology are working collaboratively to improve outcomes for people with head, neck and other cancers.

    Read Article
  • CAR T-cell therapy for advanced kidney cancer

    CAR T-cell therapy for advanced kidney cancer

    Providence Cancer Institute to open new clinical study of CAR T-cell therapy to people with clear cell renal cell carcinoma, the most common type of kidney cancer.

    Read Article
  • First-in-human immune therapy study for multiple myeloma

    First-in-human immune therapy study for multiple myeloma

    First-in-human immune therapy study at Providence Cancer Institute will assess the safety and effectiveness of talquetamab as a potential treatment for cancerous plasma cells known as multiple myeloma

    Read Article
  • Federal grant fuels research in harnessing micro-organisms for cancer immunotherapy

    Federal grant fuels research in harnessing micro-organisms for cancer immunotherapy

    Providence researchers awarded funding from National Cancer Institute to study “Bugs as Drugs.”

    Read Article
  • Providence first in Pacific NW to achieve national accreditation for Rectal Cancer Program

    Providence first in Pacific NW to achieve national accreditation for Rectal Cancer Program

    Providence Cancer Institute’s Rectal Cancer Program among the first 25 in the nation to earn accreditation from the National Accreditation Program for Rectal Cancer.

    Read Article
  • Can photo-immunotherapy improve outcomes in advanced solid tumors?

    Can photo-immunotherapy improve outcomes in advanced solid tumors?

    Providence Cancer Institute to offer a new phase I/II study of a first-in-class photoimmunotherapy for solid tumors that overexpress the epidermal growth factor receptor protein.

    Read Article
  • Providence cancer research featured at global oncology conference

    Providence cancer research featured at global oncology conference

    Researchers at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute, will join oncology professionals around the world for the 2021 ASCO Annual Virtual Conference.

    Read Article
  • Phase II study of neoadjuvant combination therapy for ovarian cancer

    Phase II study of neoadjuvant combination therapy for ovarian cancer

    Providence Cancer Institute to offer phase II clinical trial of neoadjuvant chemotherapy plus immunotherapy for patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

    Read Article
  • Neoadjuvant combination therapy for triple-negative breast cancer

    Neoadjuvant combination therapy for triple-negative breast cancer

    A phase II, investigator-initiated clinical trial at Providence Cancer Institute aims to improve survival for patients with triple-negative breast cancer. The trial is available only at Providence.

    Read Article
  • Providence researchers demonstrate antibodies to COVID-19 in breast milk of mothers following vaccination

    Providence researchers demonstrate antibodies to COVID-19 in breast milk of mothers following vaccination

    Learn about a potential immune benefit for infants from lactating mothers who have received a COVID-19 vaccine.

    Read Article
  • Combination therapy for metastatic thyroid cancer

    Combination therapy for metastatic thyroid cancer

    New clinical trial at Providence Cancer Institute combining targeted therapy with checkpoint immunotherapy for patients with metastatic thyroid cancer.

    Read Article
  • $2M endowed chair funded to help develop new treatments at Providence Cancer Institute

    $2M endowed chair funded to help develop new treatments at Providence Cancer Institute

    Michael Kelley Endowed Chair for Cancer Research awarded to Providence Cancer Institute radiation oncologist, Dr. Marka Crittenden.

    Read Article
  • Register now for SITC Advances in Cancer Immunotherapy™ Live Virtual Program

    Register now for SITC Advances in Cancer Immunotherapy™ Live Virtual Program

    Attendees will have an opportunity to connect with experts in the immunotherapy field at the live virtual event held on Thursday, April 8, 2021.

    Read Article
  • Melanoma studies: can adjuvant immunotherapy improve recurrence-free survival?

    Melanoma studies: can adjuvant immunotherapy improve recurrence-free survival?

    Three new studies at Providence Cancer Institute will investigate the benefits of adjuvant immunotherapy for patients with completely resected melanoma who are at high risk of recurrence.

    Read Article
  • Adoptive cellular therapy for head and neck cancer

    Adoptive cellular therapy for head and neck cancer

    Providence Cancer Institute is the only center in the Pacific Northwest to offer a groundbreaking study of adoptive T-cell therapy ADP-A2M4 in combination with the checkpoint inhibitor pembrolizumab.

    Read Article
  • New studies aim to improve treatments for advanced breast cancer

    New studies aim to improve treatments for advanced breast cancer

    Advancements in treatment and early detection have improved survival for women diagnosed with breast cancer. For patients with locally advanced or metastatic breast cancer, better therapies are needed

    Read Article
  • Providence researchers featured at cancer immunotherapy conference

    Providence researchers featured at cancer immunotherapy conference

    Investigators present latest research in cancer immunotherapy, receive noteworthy awards, at the 35th annual meeting of the Society for Immunotherapy of Cancer.

    Read Article
  • CAR T-cell therapy for advanced B-cell Non-Hodgkin Lymphoma

    CAR T-cell therapy for advanced B-cell Non-Hodgkin Lymphoma

    Providence Cancer Institute is one of the few highly specialized centers offering adoptive cellular therapy for hematologic malignancies. Chimeric antigen receptor (CAR) T-cell therapy is a revolution

    Read Article
  • Providence cancer research highlighted at ESMO20

    Providence cancer research highlighted at ESMO20

    Providence Cancer Institute joins oncology professionals around the world for ESMO Virtual Congress 2020, the annual meeting of the European Society for Medical Oncology, held online from September 14

    Read Article
  • loading
    Loading More...